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ABSTRACT Congenital human cytomegalovirus (HCMV) infection is a significant
cause of abnormal neurodevelopment and long-term neurological sequelae in in-
fants and children. Resident cell populations of the developing brain have been sug-
gested to be more susceptible to virus-induced cytopathology, a pathway thought
to contribute to the clinical outcomes following intrauterine HCMV infection. How-
ever, recent findings in a newborn mouse model of the infection in the developing
brain have indicated that elevated levels of proinflammatory mediators leading to
mononuclear cell activation and recruitment could underlie the abnormal neurode-
velopment. In this study, we demonstrate that treatment with tumor necrosis fac-
tor alpha (TNF-)-neutralizing antibodies decreased the frequency of CD45
Ly6Chi CD11b CCR2 activated myeloid mononuclear cells (MMCs) and the lev-
els of proinflammatory cytokines in the blood and the brains of murine CMV-
infected mice. This treatment also normalized neurodevelopment in infected
mice without significantly impacting the level of virus replication. These results
indicate that TNF- is a major component of the inflammatory response associ-
ated with altered neurodevelopment that follows murine CMV infection of the
developing brain and that a subset of peripheral blood myeloid mononuclear
cells represent a key effector cell population in this model of virus-induced in-
flammatory disease of the developing brain.
IMPORTANCE Congenital human cytomegalovirus (HCMV) infection is the most
common viral infection of the developing human fetus and can result in neurodevel-
opmental sequelae. Mechanisms of disease leading to neurodevelopmental deficits
in infected infants remain undefined, but postulated pathways include loss of neuro-
nal progenitor cells, damage to the developing vascular system of the brain, and al-
tered cellular positioning. Direct virus-mediated cytopathic effects cannot explain the
phenotypes of brain damage in most infected infants. Using a mouse model that re-
capitulates characteristics of the brain infection described in human infants, we have
shown that TNF- plays a key role in brain inflammation, including recruitment of
inflammatory mononuclear cells. Neutralization of TNF- normalized neurodevelop-
mental abnormalities in infected mice, providing evidence that virus-induced inflam-
mation is a major component of disease in the developing brain. These results sug-
gest that interventions limiting inflammation associated with the infection could
potentially improve the neurologic outcome of infants infected in utero with HCMV.
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Human cytomegalovirus (HCMV) infection, the most common viral infection ac-quired by the developing fetus, occurs in approximately 0.5 to 1% of live births in
the United States and is an important cause of brain injury in infants and children (1).
Although the clinical spectrum of neurologic disease following congenital HMCV
infection is well documented, the variability in the phenotypes of central nervous
system (CNS) sequelae coupled with limited availability of pathological specimens has
resulted in an incomplete understanding of the mechanism(s) of CNS disease. The
susceptibility of the developing CNS to CMV infection has been suggested to be a
determinant of pathogenic outcomes in humans and animal models (2–18). In rodent
models, CNS structural damage is associated with infection early in development (19).
Similarly, human studies have suggested that maternal infection early in gestation is
more commonly associated with structural damage in the brains of infected infants (20,
21). However, clinical studies have indicated that significant structural brain abnormal-
ities are present in only a minority of infants with CNS sequelae following congenital
HCMV infection, suggesting that mechanisms of disease other than the loss of CNS
parenchyma are operative in the majority of infected infants (1, 22). Additionally,
transmission of HCMV to the fetus occurs more frequently during the later stages
of gestation, when the morphogenesis of major regions of the brain is nearly
complete (20). Together, these observations suggest that CNS disease and long-
term sequelae in the majority of infants with congenital HCMV infection likely arise
from mechanisms other than direct viral cellular damage and loss of parenchyma in
the developing brain.
Histological studies of tissue from fetuses and infants with fatal congenital HCMV
have demonstrated mononuclear cell (MNC) infiltrates in the CNS, suggesting that host
inflammatory responses contribute to the pathogenesis of infection (11, 23–25). More-
over, these studies also described a limited number of virus-infected cells within the
CNS, indicating that virus-induced cellular cytopathology cannot account for the global
and, importantly, the symmetric involvement of the brain in congenitally infected
infants (11, 23–25). We have previously described a murine model of congenital HCMV
infection in which newborn mice infected peripherally with nonlethal inocula of murine
cytomegalovirus (MCMV) develop focal encephalitis with histological findings nearly
indistinguishable from those reported in congenitally infected human infants (26, 27).
Although focal infection can be found in all regions of the brain, MCMV-infected
newborn mice exhibit measurable abnormalities in CNS development that are most
readily observed in the cerebellum, presumably because that region of the murine
brain undergoes extensive development during the time frame of MCMV infection in
this model (26, 27). In the model, we have described a robust inflammatory response
in the brains of MCMV-infected mice characterized by the infiltration of activated
mononuclear cells and the expression of a large number of proinflammatory cytokines
and interferon-regulated genes (IRGs) (26, 28). More recently, we demonstrated that
corticosteroid treatment of infected mice decreased inflammation and normalized
abnormalities in CNS development (29). Importantly, treatment did not alter the levels
of virus replication in the CNS of infected mice during the time frame of treatment,
suggesting that inflammation induced by infection, and not virus-induced cytopathol-
ogy, was responsible for developmental abnormalities in the brain (29). While the
specific targets of the anti-inflammatory effects of corticosteroid treatment in the
model remain undefined, infection-induced soluble inflammatory mediators, including
tumor necrosis factor alpha (TNF-), gamma interferon (IFN-), and IFN-, were de-
creased (29). Because of the potential toxicity of corticosteroids for the developing CNS,
as well as the off-target effects of corticosteroids that have been documented in clinical
studies and in animal models, we sought more targeted approaches to decrease CNS
inflammation in infected mice (30–32). We focused our studies on responses associated
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with TNF- because pathway analyses of the transcriptome from cerebella of infected
mice revealed that TNF- represented a central node in the pathway of the observed
inflammatory responses (26).
TNF- is induced following MCMV infection and can function in the control of virus
replication (33–36). A direct antiviral effect of TNF- on CMV replication in primary
human astrocytes has been documented in vitro (37). Indirect mechanisms responsible
for the antiviral activities of TNF- in MCMV-infected mice have also been proposed,
such as facilitating the infiltration of monocytes/macrophages and CD8 T lympho-
cytes into sites of infection and increasing mononuclear cell activation (38, 39). Simi-
larly, in other viral infections, TNF- has also been shown to have a protective role. The
results from studies in a murine model of viral encephalitis have shown that TNF-
facilitates recruitment of monocytes/macrophages into the CNS of West Nile virus
(WNV)-infected mice (38). Treatment of infected mice with neutralizing TNF- antibod-
ies increased the mortality in infected mice, suggesting an important role for TNF-
early in the control of virus infection in the brain, presumably through its effect on the
recruitment of inflammatory monocyte/macrophage populations (38). TNF- has also
been shown to be protective in murine models of herpes simplex virus (HSV) enceph-
alitis and in clearance of lymphocytic choriomeningitis virus (LCMV) (40, 41). In contrast
to these findings, other studies have argued that TNF- facilitates WNV neuroinvasion
by disrupting the integrity of the blood-brain barrier, a mechanism that may also
contribute to increases in mononuclear cell infiltration into the infected CNS (42). In
contrast to antiviral responses, TNF- expression in the CNS has also been associated
with both neurodegenerative and neurodevelopmental diseases. Both direct and indi-
rect neurotoxic effects of TNF- in culture systems have been reported, and TNF- has
been proposed to contribute to neurodegeneration observed in HIV-associated de-
mentia (43–50). Transgenic mice constitutively expressing TNF- in the CNS exhibit
severe inflammation and associated histopathological findings, including microgliosis
with infiltrating macrophages (51). Importantly, histological changes in these mice were
modified by peripheral administration of a TNF--neutralizing antibody (TNF-NAb) (51).
Neuronal overexpression of TNF- has been associated with increased cytokine pro-
duction and lower seizure thresholds in Borna virus-infected rodents (52). TNF-
neurotoxicity has been associated with the recruitment of inflammatory monocytes to
sites of inflammation in the brain, similar to its pathogenic function in other organ
systems (53, 54). Together, these studies suggest that a balance exists between
protective host responses and pathogenic inflammation associated with TNF- expres-
sion. Importantly, the balance between protective responses and disease is variable
depending on the organ that is involved, and in the case of the brain, the develop-
mental status of the brain during virus-induced inflammation.
In the present study, we used TNF-NAbs to explore the role of TNF- in altered CNS
development following MCMV infection of the developing CNS. MCMV-infected mice
were treated with TNF-NAbs, and the effects on virus replication, the induction of
inflammatory responses, and cerebellar development during the early postnatal period
were determined. Our findings indicated that neutralization of TNF- did not signifi-
cantly alter the levels of virus replication during the time interval of our experiments
but decreased CNS inflammation associated with MCMV infection. Notably, neutraliza-
tion of TNF- resulted in a significant decrease in activated blood myeloid mononuclear
cells (MMCs) (CD45int Ly6Chi CD11b CCR2) that trafficked into the CNS, suggesting
that the infiltration of these cells into the CNS of MCMV-infected mice was a major
component of inflammation in the brains of MCMV-infected newborn mice. Moreover,
treatment of infected mice with TNF-NAb normalized previously described develop-
mental abnormalities in the cerebellum, providing further evidence that host inflam-
matory responses, specifically those associated with TNF-, following MCMV infection
were a major component of the mechanism(s) leading to alterations in developmental
programs of the brain.
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TNF-NAb treatment of MCMV-infected newborn mice decreases the inflamma-
tory response in the cerebellum without altering virus replication. MCMV infection
of newborn mice results in hematogenous spread to the brain, with peak levels of virus
in the brain detected on postnatal day (PND) 8 and the induction of proinflammatory
responses in the brain that also peak on PND 8 (26, 29). We initially analyzed the
transcription and protein levels of a subset of proinflammatory cytokines and chemo-
kines involved in mononuclear cell recruitment and confirmed previously described
increases in the transcription of the proinflammatory cytokine genes TNF-, interleukin
1 (IL-1), and IFN- and the chemokine genes MCP-1 and RANTES in the cerebella of
PND 8-infected mice (Fig. 1A) (26). Protein levels of TNF-, MCP-1, RANTES, and IFN-
were also increased in cerebella from MCMV-infected mice (Fig. 1B). Serum TNF-,
MCP-1, RANTES, IFN-, and, to a lesser extent, IL-1 levels also increased over the course
of acute infection (Fig. 1C). The increased expression of chemokines associated with
mononuclear cell recruitment to the CNS (MCP-1 and RANTES) was consistent with
previous descriptions of the infiltration of myeloid and lymphoid cells into the CNS
following MCMV infection (28, 29).
As was noted previously, pathway analysis, using commercially available software
(Ingenuity; Qiagen), of the transcriptome derived from the cerebella of MCMV-infected
mice indicated that TNF- represented a critical regulatory molecule in the inflamma-
tory responses (26, 28, 29). To define the role of TNF- signaling in proinflammatory
responses in the cerebellum, we treated MCMV-infected and uninfected (control) mice
with TNF-NAbs on PND 4 to 7 and assayed the transcription of genes encoding
proinflammatory molecules in the cerebella from PND 8 mice. The expression of TNF-,
as well as IL-1, MCP-1, RANTES, IFN-, IFN-, and STAT1, RNA was decreased in the
cerebella of TNF-NAb-treated infected mice (Fig. 2A). Given the reported roles of IFN-,
IFN-, and STAT1 in the control of virus replication, we expected that downstream
genes involved in antiviral responses would also be decreased in the brains of infected
FIG 1 Increased inflammatory responses following MCMV infection of newborns. (A and B) Transcription (A) and protein levels (B) of
proinflammatory mediators in the cerebella of control and MCMV-infected PND 8 mice. The P values were calculated using a two-tailed
t test. (A) qPCR of cerebellar mRNA. The data are shown as mean fold changes  standard errors of the mean (SEM) normalized to
vehicle-treated control; n  5 to 7 mice/group. (B) Cytokine/chemokine levels in cerebellar homogenates. The data are shown as medians
with interquartile ranges; n  3 cerebella/sample with 3 replicates/group. Conc., concentration. (C) Serum concentrations of cytokines/
chemokines during acute infection. The data are shown as means  SEM; n  3 mice/group. The P values were calculated using two-way
ANOVA with Bonferroni posttests.
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mice treated with TNF-NAbs; however, treatment had little effect on the transcription
of IFIT1 or IRF7 in the cerebella of infected mice (Fig. 2B). Thus, in contrast to our
previous results from studies using corticosteroid treatment to reduce CNS inflamma-
tion in infected mice, TNF-NAbs appeared to exhibit somewhat more specificity in the
regulation of proinflammatory responses in the cerebella of MCMV-infected neonatal
mice (29).
To determine if the reduction in the expression of proinflammatory molecules
following neutralization of TNF- was associated with increased virus replication in
MCMV-infected mice, we quantified MCMV replication in the livers, spleens, and brains
of infected mice (29). With the exception of a small decrease in viral DNA in the brains
of infected mice treated with isotype control antibodies (IC), statistically insignificant
changes in viral genome copy numbers were observed in the livers, spleens, brains, and
cerebella of infected mice following TNF-NAb treatment compared to vehicle or isotype
control antibody-treated infected animals (Fig. 2C). Together, these data indicated that
treatment of MCMV-infected newborn mice with TNF-NAbs modulated inflammatory
responses in the brain but did not result in a significant change in the levels of virus
replication in multiple organs, including the brain cortex and cerebellum.
Neutralization of TNF- corrects developmental deficits in the cerebella of MCMV-
infected neonatal mice. To investigate the contribution of TNF- to inflammation-
associated abnormalities in CNS development following MCMV infection, we analyzed
cerebellar morphogenesis in infected mice following TNF-NAb treatment. As we have
reported previously, the cerebellar area, external granule cell layer (EGL) thickness, and
FIG 2 Treatment of MCMV-infected mice with TNF-NAbs decreases inflammatory responses in the cerebellum. (A and B) Transcription of
proinflammatory cytokines and chemokines (A) and interferon-regulated genes (B) in the cerebella from control and MCMV-infected mice
treated with vehicle or with isotype or TNF-NAbs. The fold change was normalized to the vehicle-treated control. The data are shown as
means  SEM. The P values were calculated by two-way ANOVA with Bonferroni posttests; n  5 mice/group. (C) Median MCMV genome
copy numbers (log10) in infected mice treated with vehicle or with isotype or TNF-NAbs. The P values were calculated using a Kruskal-Wallis
test of medians with Dunn posttest correction; n  25 to 35 mice/group for liver, spleen, and brain; n  5 mice/group for cerebellum.
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granule neuron progenitor cell (GNPC) number were altered in MCMV-infected new-
born mice compared to these values in uninfected control mice (Fig. 3A to C and F) (26,
29). Treatment of infected mice with TNF-NAbs resulted in the normalization of these
morphological abnormalities (Fig. 3A to C and F). Importantly, treatment with TNF-
NAbs had no effect on cerebellar morphogenesis in control animals (Fig. 3A to C and
F). Similarly, treatment with isotype antibodies did not alter the abnormal cerebellar
development observed in MCMV-infected mice or normal cerebellar development in
control mice (Fig. 3A to C).
Previously we demonstrated that altered cerebellar morphogenesis in infected mice
was associated with abnormalities in GNPC proliferation in the EGL of the cerebellar
cortex. Altered GNPC proliferation was characterized by decreased bromodeoxyuridine
(BrdU) incorporation without significant changes in the percentage of actively cycling
(Ki67) GNPCs (29). Consistent with these results, fewer GNPCs were BrdU in cerebella
following MCMV infection, while the percentage of cycling (Ki67) GNPCs remained
unchanged compared to control animals (Fig. 3D and E) (29). Treatment of infected
mice with TNF-NAbs normalized the frequency of BrdU GNPCs in the EGL (Fig. 3D and
E). Treatment with isotype control antibodies had no effect on altered proliferation of
cerebellar GNPCs following infection (Fig. 3D and E). These results strongly argued that
neutralizing TNF- with TNF-NAbs restored the proliferative capacity of GNPCs in the
cerebella of MCMV-infected mice, likely contributing to the normalization of the
FIG 3 TNF-NAbs normalize abnormalities in cerebellar development following MCMV infection. (A) Cerebellar area of control for infected
mice treated with vehicle or with isotype or TNF-NAbs. Five sections were analyzed/mouse; n  5 mice/group. (B) Cerebellar EGL
measurements from vehicle-, isotype-, or TNF-NAb-treated control and infected mice (32 measurements/mouse). (C) GNPC counts in the
EGL of vehicle-, isotype-, and TNF-NAb-treated control and infected mice; 8 sections were analyzed/mouse. (D and E) Quantification of
Ki67 (D) and BrdU (E) GNPCs in the EGL of control and MCMV-infected mice treated with vehicle or with isotype or TNF-NAbs; 8 sections
were analyzed/mouse. (B to E) n  3 mice/group for vehicle- treated animals; n  5 mice/group for isotype- or TNF-NAb-treated animals.
The data are shown as means  SEM. The P values were calculated by two-way ANOVA with Bonferroni posttests. (A to C and E)
Vehicle-treated infected mice were significantly different (P  0.05) from vehicle-treated control mice, as determined by two-tailed t test.
(F) Representative confocal images showing the thickness of the EGL (arrow) following vehicle, isotype, or TNF-NAb treatment of control
and MCMV-infected mice. Images, 60 magnification.
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parameters of cerebellar morphogenesis. No differences were observed in the percent-
age of cycling (Ki67) GNPCs entering S phase (BrdU) following isotype antibody or
TNF-NAb treatment of control mice (Fig. 3D and E).
Morphological deficits in the cerebella of infected mice also coincided with altered
transcription of several developmentally regulated genes within GNPCs. Corticosteroid
treatment normalized transcription of these genes (26, 29). Consistent with these
findings, the transcription of two genes used to monitor GNPC differentiation, GABRA6
and CDK5, was decreased following infection (Fig. 4) (55–59). The expression of both
GABRA6 and CDK5 was normalized in the cerebella of infected mice following TNF-NAb
treatment (Fig. 4). In addition, transcription of N-myc and gli1, two genes in the sonic
hedgehog (Shh) pathway of GNPC proliferation, was increased in the cerebella of
infected mice (Fig. 4). Treatment with TNF-NAbs reduced the transcription of both
genes to levels comparable to those in control mice (Fig. 4) (29). Treatment with isotype
antibodies did not alter the transcription of these genes in the cerebella of control or
infected mice (Fig. 4). No differences were noted in the expression of gli1 or CDK5 in
control animals treated with vehicle or isotype control antibody; however, treatment
with TNF-NAbs increased the expression of gli1 and CDK5 in control mice (Fig. 4). We
have not determined the mechanism for this apparent off-target effect on gli1 and
CDK5 expression in control mice treated with TNF-NAbs, but it is important to note that
the effect was an increase in transcription above what was observed in vehicle-treated
MCMV-infected mice. This result suggested that the effect was unrelated to the
normalization (decreased expression) of gli1 expression in MCMV-infected mice treated
with TNF-NAbs (Fig. 4). Increased expression of CDK5 in control animals following
TNF-NAb treatment was not statistically different than CDK5 expression in control
animals treated with isotype control antibody, arguing that this off-target effect was
not mediated specifically by TNF-NAbs (Fig. 4). As a control, the transcription of Tiam1,
a guanine nucleotide exchange factor expressed in GNPCs during cerebellar develop-
ment and involved in GNPC migration, was assayed (60, 61). Transcription of Tiam1
remained unaltered across all experimental treatment groups, suggesting specificity in
the observed transcriptional changes for gene pathways involved in GNPC proliferation.
These data demonstrated that neutralizing TNF- in infected mice normalized abnor-
malities in morphogenesis, GNPC proliferation, and developmental gene transcription
FIG 4 TNF-NAb treatment of MCMV-infected mice normalizes developmental gene expression in the cerebellum. Shown are
transcription levels of developmentally regulated genes in the cerebella of vehicle-, isotype-, or TNF-NAb-treated control and
infected mice. The data are shown as means  SEM. Statistical significance was calculated using two-way ANOVA with Bonferroni
posttest; n  5 mice/group. Vehicle-treated infected mice were significantly different (P  0.05) from vehicle-treated control mice
as determined by two-tailed t test (excluding Tiam1). n.s., not significant.
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in the cerebellum, supporting our hypothesis that TNF- and/or downstream effectors
contributed to the altered cerebellar development in MCMV-infected newborn mice.
TNF-NAb treatment of MCMV-infected mice results in decreased CNS infiltra-
tion of activated inflammatory monocytes, nonclassical monocytes, and lymphoid
cells. Earlier studies in this model system demonstrated that focal mononuclear cell
infiltrates were widely distributed throughout the brain, including the cerebellum, and
often associated with MCMV-infected resident cells of the CNS (26, 62). The finding that
treatment with TNF-NAbs decreased CNS inflammation and normalized cerebellar
development in MCMV-infected newborn mice raised the possibility that TNF-NAbs
limited CNS inflammation by decreasing mononuclear cellular infiltrates into the CNS of
MCMV-infected mice, similar to our findings in a previous study in which corticosteroids
were used to dampen inflammation (29). Cells of the myeloid lineage (Iba-1), includ-
ing microglia, were identified in tissue sections from the brains of PND 8 mock- and
MCMV-infected mice, as well as mice treated with TNF-NAbs. Significant increases in the
numbers of Iba-1 cells in the brains of infected mice were observed compared to
mock-infected mice, regardless of whether they were treated with TNF-NAbs (Fig. 5A
and B). When the population of Iba-1 cells was further analyzed for the expression of
CD169, a myeloid marker expressed by peripheral blood monocytes but not by resident
microglia, we noted that approximately 20% of Iba-1 cells in cerebellar sections from
FIG 5 TNF-NAb treatment decreases CD169 Iba-1 monocytes in the CNS of MCMV-infected mice. (A)
Immunofluorescence detection of Iba-1 (green), CD169 (red), and Hoechst (blue) cells in the cerebella
of vehicle-treated control mice and vehicle-, isotype-, and TNF-NAb-treated infected mice analyzed by
confocal microscopy. Magnification, 40; scale bars  50 m. (B and C) Quantification of Iba-1 cells (B)
and the percentages of CD169 cells within the Iba-1 population (C) in the cerebella of vehicle-,
isotype-, or TNF-NAb-treated control and infected mice; 4 sections were counted/animal; n  5
mice/group. The graphs show means  SEM. The P values were calculated using two-way ANOVA with
Bonferroni posttest.
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MCMV-infected mice also expressed CD169 (Fig. 5A and C). Treatment of MCMV-
infected mice with TNF-NAb significantly decreased the population of Iba-1 CD169
cells but only minimally decreased the total numbers of Iba-1 cells in the cerebella of
infected mice (Fig. 5A and C). This finding suggested that TNF-NAbs could decrease
inflammation in the CNS of infected mice by limiting recruitment of peripheral blood
monocytes to the brains of MCMV-infected mice. Together, these results suggested that
peripheral blood monocytes contributed to the immunopathology associated with
MCMV infection in the developing brains of neonatal mice.
To further investigate the role of peripheral blood monocytes in the altered cere-
bellar development in MCMV-infected mice, we used flow cytometry to quantify MNCs
isolated from the brains of treated and control animals. In these studies, we took
advantage of the cell surface antigen Ly6C, which is differentially expressed in classical
and nonclassical peripheral blood monocytes, natural killer (NK) cells, and subsets of
activated lymphocytes (63–66). Importantly, previous studies have reported that Ly6C
is not expressed by CNS-resident microglia (67). Resident microglia (Ly6C) and infil-
trating MNCs (Ly6C) were distinguished by gating Ly6C with CD11b (Fig. 6A). Differ-
FIG 6 Decreased infiltration of myeloid and lymphoid cells in the CNS of MCMV-infected mice treated with TNF-NAb.
(A) Representative flow cytometry dot plots showing the frequency of cells expressing CD11b Ly6C cells gated on
total live CD45 mononuclear cells isolated from the brains of uninfected or MCMV-infected mice left untreated or
treated with isotype or TNF-NAbs. The gates labeled 1, 2, and 3 in the uninfected (CNTRL) plot identify the nc-Mo and
iMo subsets in the upper right quadrant and the lymphoid subset in the lower right quadrant. The numbers next to
the gates correspond to representative percentages of each cell subset. (B to E) Quantifications depicting, out of total
(CD45) MNCs, the percentages of total (Ly6Cint/hi) brain-infiltrating MNCs (B), nc-Mo (CD11b Ly6Cint) (C), iMo
(CD11b Ly6Chi) (D), and lymphoid cells (CD11blow/ Ly6Cint) (E). The data are shown as means  SEM; n  2 or 3
replicates, with 4 mice pooled per replicate. The P values were calculated using two-way ANOVA, with Bonferroni
posttests.
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ential expression of Ly6C and CD11b in the infiltrating subset allowed the resolution of
3 subsets of mononuclear cells: myeloid patrolling or nonclassical monocytes that
expressed CD11b and intermediate levels of Ly6C (nc-Mo) (CD11b Ly6Cint) (Fig. 6A);
classical or inflammatory monocytes expressing CD11b and the highest levels of Ly6C
(iMo) (CD11b Ly6Chi) (Fig. 6A); and lymphoid cells, expressing intermediate levels of
Ly6C and either low or nondetectable levels of the myeloid marker CD11b (CD11blow/
Ly6Cint) (Fig. 6A). The differential expression of CD45, a surface marker that has been
used to differentiate between brain-resident (CD11b CD45int/lo) and infiltrating
(CD11b CD45hi) MNC subsets in earlier studies, in brain MNCs was also noted
(references 28, 29, and 68 and data not shown). Consistent with previous findings,
MCMV infection induced a robust immune response in the neonatal brain, as indicated
by an increase in the frequencies of both myeloid (CD45int CD11b Ly6Cint/hi) and
lymphoid (CD45hi CD11blow/ Ly6Cint) cells infiltrating the brain compared to unin-
fected controls (Fig. 6A and B). Further analysis of the CD45hi CD11blow/ Ly6cint subset
revealed that about 50% of these cells were NKp46 CD3, indicating that they were
NK cells (data not shown). Analysis of the individual infiltrating subsets revealed that
after MCMV infection, the average frequencies of the nc-Mo, iMo, and lymphoid subsets
increased 3.6-, 11.5-, and 12.8-fold, respectively, compared to the corresponding fre-
quencies in uninfected mice (Fig. 6A, C, D, and E). In mice treated with TNF-NAbs, the
frequency of infiltrating MNCs was decreased to approximately half of that of the
average frequencies observed in untreated, infected animals (Fig. 6A and B). In infected
mice treated with TNF-NAbs, infiltrating nc-Mo, iMo, and lymphoid subsets decreased
by 54%, 71%, and 60%, respectively, relative to the respective frequencies in untreated,
infected animals (Fig. 6C, D, and E). Mice treated with the IC exhibited a smaller,
nonsignificant decrease in the same subsets of mononuclear cells. These results indi-
cated that each MNC subset identified in the MCMV-infected brain infiltrate was
significantly decreased following systemic treatment with TNF-NAbs (Fig. 6).
In murine models of CNS disease, either degenerative or as a result of viral infection,
the infiltration of activated monocytes defined as blood-derived MNCs expressing
Ly6Chi and CCR2 (iMo) has been associated with sustained inflammation and increased
pathology (67, 69–74). We next analyzed the activation state of iMo infiltrating the CNS
of MCMV-infected newborn mice before and after TNF-NAb treatment by measuring
the expression of the CCR2 receptor, the major histocompatibility complex class II
(MHC-II), and the costimulatory molecule CD80. Following MCMV infection, the average
frequency of iMo in brains from infected mice that expressed MHC-II was 18.8%,
whereas MHC-II was not detected in iMo from uninfected mice (Fig. 7A). Similarly, the
frequencies of iMo expressing CD80 and CCR2 were increased 4.4- and 3.4-fold,
respectively, compared to the frequencies of iMo expressing these markers in unin-
fected controls (Fig. 7C and E). The average median fluorescence intensity (MFI) values
of MHC-II, CD80, and CCR2 were also increased over the average MFI values in cells from
uninfected animals (Fig. 7B, D, and F). Importantly, following TNF-NAb treatment, the
frequencies and MFI values of iMo expressing MHC-II, CD80, and CCR2 did not decrease
significantly compared to untreated or IC-treated controls (Fig. 7). Thus, in this model
system, TNF-NAb treatment significantly reduced the infiltration of MNCs into the
brains of MCMV-infected mice, including the number of infiltrating iMo, but did not
significantly alter the level of activation of iMo in the infected brain. These findings
suggested that the impact of TNF-NAb on brain inflammation in this model was at the
level of recruitment of iMo into the brains of MCMV-infected animals and not secondary
to activation of MNCs that infiltrated the brain.
Decreased frequency of Ly6Chi CCR2 inflammatory Mo in peripheral blood of
TNF-NAb-treated mice. The decreased frequencies of nc-Mo, iMo, and lymphoid
subsets observed in the brains of MCMV-infected mice treated with TNF-NAbs could be
explained by decreased frequencies of these subsets of MNCs in peripheral blood,
resulting in decreased recruitment to the brain. To address this possibility, we analyzed
the frequencies of MNCs in peripheral blood of uninfected and MCMV-infected animals
treated with TNF-NAbs or IC. In our analysis of CD45 MNCs that also expressed Ly6C
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and CD11b, we identified four MNC subsets in the blood of newborn mice: (i) nc-Mo,
(ii) iMo, (iii) lymphoid cells, and (iv) CD45 cells that did not express CD11b or Ly6C (Fig.
8A). On day 8 post-MCMV infection (PND 8), the frequency of the Ly6C-expressing cells
increased 2.5-fold compared to uninfected mice, demonstrating a robust systemic
response to infection (Fig. 8A). Concomitantly, the frequency of the CD11b Ly6C
subset decreased 3-fold compared to that in uninfected mice (Fig. 8A and data not
shown). Compared to the respective frequencies in uninfected mice, the frequencies of
nc-Mo, lymphoid cells, and iMo all increased significantly, confirming MCMV-induced
activation of the myeloid and lymphoid components of the immune response in
infected newborn mice (Fig. 8B). Following treatment of the MCMV-infected mice with
TNF-NAbs or IC, the frequency of the nc-Mo subset was unchanged compared to that
in untreated mice (Fig. 8B). While the frequency of the lymphoid subset in TNF-NAb-
treated mice appeared to be decreased relative to that in untreated mice, it did not
differ statistically from the frequency observed in IC-treated mice (Fig. 8B). In contrast,
treatment with the TNF-NAbs resulted in a decrease in the frequency of iMo by more
than 50% relative to infected untreated mice and IC-treated mice (Fig. 8A and B). This
result suggested that TNF-NAbs preferentially impacted the iMo subset within periph-
eral blood. The frequency of cells that expressed the chemokine receptor CCR2 was
then determined, as the presence of Ly6Chi CCR2monocytes has been associated with
inflammation in the periphery, as well as within the CNS (67, 69, 75, 76). Interestingly,
nearly all Ly6Chi monocytes expressed CCR2, while virtually none of the Ly6Cint
monocytes expressed the chemokine receptor (Fig. 8C and D). The frequency of Ly6Cint
CCR2monocytes (nc-Mo) remained unchanged by TNF-NAb treatment (Fig. 8C and D).
Following treatment with TNF-NAbs, the frequency of Ly6Chi CCR2 monocytes in
MCMV-infected mice decreased significantly relative to untreated mice (Fig. 8D). In
mice that were treated with IC, we observed a minimal but significant decrease in the
frequency of this subset compared to untreated mice, suggesting that some of the in
vivo effects of TNF-NAbs were nonspecific (Fig. 8D). Together, these data indicated that
treatment with TNF-NAbs preferentially decreased the frequency of iMo in the periph-
eral blood of MCMV-infected mice and suggested that the reduced recruitment of iMo
into the brain in this model of virus-induced inflammation was secondary to TNF-NAb
effects on iMo in peripheral blood.
Neutralization of TNF- correlates with decreased frequency of activated mi-
croglia in the brains of MCMV-infected neonatal mice. In addition to infiltrating
FIG 7 iMo that infiltrate the brains of MCMV-infected mice remain activated following TNF-NAb treatment. (A, C, and E) Frequencies of
iMo gated as total live (CD45¡CD11b Ly6C¡CD11b Ly6Chi) cells that expressed MHC-II (A), CD80 (C), and CCR2 (E) that were
isolated from the brains of uninfected and MCMV-infected mice, untreated or treated with isotype control or TNF-NAbs. (B, D, and F)
Quantification of expression of MHC-II (B), CD80 (D), and CCR2 (F) as MFI in iMo isolated from uninfected and MCMV-infected mice that
were untreated or treated with isotype control or TNF-NAbs. The graphed data represent 2 or 3 replicates per group, with 4 mice
pooled/replicate. The P values were calculated using two-way ANOVA with Bonferroni posttest correction.
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activated iMo, the activation of microglia has also been linked to increased CNS
pathology in neurodegenerative, autoimmune, and infectious diseases (72, 77). In
MCMV infection of the developing CNS, we have described robust MCMV-induced
microglial activation indicated by upregulation of MHC-II molecules (28, 29). Consistent
FIG 8 TNF-NAb treatment decreases the frequency of inflammatory monocytes (CD11b Ly6Chi CCR2) but not that of nonclassical
monocytes or lymphocytes in blood of MCMV-infected newborn mice. (A and B) Representative flow cytometry dot plots showing
peripheral blood subsets of uninfected or MCMV-infected mice that were left untreated or treated with TNF-NAbs or isotype control. (A)
Expression of CD11b and Ly6C out of total (CD45) mononuclear cells. (B) corresponding quantification of iMo, nc-Mo, and lymphoid cells.
(C) Expression of CCR2 and Ly6C within the myeloid compartment containing nc-Mo and iMo, gated on total CD45¡SSC-A/CD11b cells.
(D) Corresponding quantification. The numbers within the dot plot quadrants are representative percentages of the corresponding MNC
subsets. The data are shown as means  SEM; n  2 or 3 replicates, with 4 mice pooled per replicate. The P values were calculated using
two-way ANOVA, with Bonferroni posttests.
Seleme et al. Journal of Virology
April 2017 Volume 91 Issue 8 e01983-16 jvi.asm.org 12
 o
n






with previous findings, MCMV infection induced an 7-fold increase in the frequency
of MHC-II microglial cells (Ly6C CD11b CD45low) compared to that in uninfected
mice, whereas the proportion of resting microglia (MHC-II) decreased in MCMV-
infected mice compared to uninfected mice (Fig. 9A, B, and D). Similarly, the frequency
of CD80 microglial cells increased by nearly 4-fold following MCMV infection com-
pared to uninfected mice (Fig. 9C). Following treatment with TNF-NAb, the frequency
of MHC-II microglial cells decreased to levels that were similar to the average
frequency observed in uninfected mice, and the fraction of resting MHC-II microglia
was similar to that observed in uninfected animals (Fig. 9B and D). The average MHC-II
MFI value of activated microglia isolated from infected TNF-NAb-treated mice de-
creased significantly compared to the average MFI levels observed in untreated,
infected, or IC-treated mice (Fig. 9B). Together, these results indicated that TNF-NAb
treatment resulted in a decrease of activated microglia, further supporting our initial
hypothesis that TNF- is a major inflammatory mediator in the CNS of MCMV-infected
neonatal mice.
iMo expresses the highest levels of TNF- among all MNC subsets isolated
from brain and blood. We next determined which specific MNC subset isolated from
the brains or blood of PND 8 MCMV-infected mice expressed TNF- and thus could be
targeted by the TNF--neutralizing activities of TNF-NAb and/or possibly by effector
functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) directed
against cells expressing membrane-bound TNF- (78, 79). MNC isolates from brain or
FIG 9 Decreased frequency of activated resident microglia in the brains of TNF-NAb-treated MCMV-infected mice. (A)
Representative flow cytometry dot plots showing microglial cells, gated (CD45 CD11b Ly6C) and defined, respectively, as
activated (MHC-II expression [MHC-II]) or resting microglia. Representative cell percentages are shown within each quadrant.
The histograms (insets) show MHC-II cell expression versus MHC-II antibody isotype controls. The cells analyzed were isolated
from the brains of uninfected or MCMV-infected mice that were left untreated or treated with isotype or the TNF-NAbs. (B and
C) Quantification of the percentages of activated (]MHC-II) microglia and MHC-II MFI levels (B) and percentages of CD80
activated microglia (C). (D) Resting microglial cells, defined as MHC-II, gated as described for panel A. The data represent 2
or 3 replicates per group, with 4 mice pooled/replicate. The P values were calculated using two-way ANOVA, with Bonferroni
posttests.
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blood were sorted by fluorescence-activated cell sorter (FACS) according to their
expression of CD45, CD11b, and Ly6C, and the expression of TNF- RNA was quantified
(Fig. 10). Relative gene expression was quantified by comparison of TNF- expression
levels in microglial cells as a reference for MNCs isolated from the brains of infected
mice. Among microglial, lymphoid, nc-Mo, or iMo MNC subsets from the brain, the
highest level of TNF- expression was seen in the iMo (Fig. 10A). This result indicated
that among the MNCs present in the brains of MCMV-infected newborn mice, iMo and
microglial cells represented the primary sources of proinflammatory TNF-. In MNC
subsets sorted from blood, the relative expression of TNF- was again highest in iMo
(Fig. 10B). Finally, blood- and brain-derived lymphoid cells expressed low levels of
TNF- (Fig. 10A and B). To validate the correct biological assignment of the different cell
subsets that were isolated by sorting, we analyzed the expression of IP10, encoding a
T-cell chemoattractant that has been reported to be expressed primarily by activated
monocytes, macrophages, or dendritic cells, and IFN-, encoding another cytokine
highly associated with inflammation and typically expressed by effector NK and CD8 T
cells. The iMo subsets in both brain and blood MNCs expressed high levels of IP10 (Fig.
10A and B). In contrast, these cell subsets expressed the lowest levels of IFN- (Fig. 10A
and B). These results suggest that among MNCs present at this time, the brain and
blood iMo were activated by proinflammatory monocytes and produced the highest
levels TNF- and other proinflammatory marker genes, such as IP10. The microglial
subset expressed IP10, consistent with the function of activated microglia in the
recruitment of effector leukocytes (Fig. 10A) (80). In contrast, IFN- expression was not
detected in the microglial subset, and the level of expression of IFN- in nc-Mo was
modest in comparison to the level of expression detected in lymphocytes present in the
brain (Fig. 10A). Both brain- and blood-derived lymphoid subsets expressed low levels
of IP10 (Fig. 10A and B). Together, these data raise the possibility that TNF-NAbs could
impact CNS inflammation, not only by limiting recruitment of iMo to the brain and
modulating microglial activation, but also by either neutralizing soluble TNF- in the
brain or targeting TNF--expressing cells in the MCMV-infected brain.
FIG 10 Proinflammatory molecules are differentially expressed in mononuclear cell subsets isolated from peripheral blood or brains of
MCMV-infected newborn mice. Shown are representative flow cytometry dot plots of brain-derived (A) and blood-derived (B) mononu-
clear cell subsets that differentially expressed Ly6C and/or CD11b that were gated on total (CD45) mononuclear cells. The different cell
populations were sorted according to their expression of the surface markers Ly6C and CD11b. The graphs show the relative expression
of TNF-, IP10, or IFN- in subsets derived from brain (A) or blood (B). (A) The microglial subset was used to set the comparative reference
value, with the exception of the IFN- expression, for which the response of the nc-Mo subset was used because IFN- expression was
not observed in the microglial subset. (B The immature MNC mixture was set as the comparative reference sample. In all assays, the
housekeeping gene -actin was used as an internal reference control.
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Animal models have provided insight into the proposed disease mechanisms of
congenital HCMV infection, but each model has limitations, and none completely
recapitulates human infection (3, 4, 9, 81–84). To address the shortcomings of previ-
ously described small-animal models, particularly those that relied on direct intracranial
inoculation of virus, we developed a murine model of congenital HCMV infection
utilizing peripheral (intraperitoneal) inoculation of newborn mice with nonlethal doses
of MCMV (26). The model was developed in newborn mice because the neurodevel-
opmental status of mice at this age has been shown to be nearly equivalent to that of
a late second trimester human fetus (85). Thus, the immaturity of the CNS in newborn
mice has enabled us to experimentally explore the impact of infection and virus-
induced inflammation of the brain during a dynamic period of neurodevelopment. In
addition, the model recapitulates the hematogenous route of CNS infection following
intrauterine HCMV infection of the human fetus. The replication of MCMV in brains of
infected mice resulted in a robust inflammatory response and a number of neurode-
velopmental abnormalities ranging from delayed expression of developmentally reg-
ulated genes to altered cellular positioning in the cerebellum (26, 29). Utilizing this
mouse model, we have shown that treatment of infected mice with prednisolone, a
relatively nonspecific anti-inflammatory agent, normalized deficits in cerebellar devel-
opment associated with MCMV infection (29). In addition, prednisolone treatment
decreased both expression of inflammatory mediators in the cerebellum and the
frequency of CD45 CD11b mononuclear cells in the brains of infected mice. Because
the level of virus replication in the CNS was not altered by this short-term corticosteroid
treatment, these results argued that virus-induced inflammatory responses, and not
direct viral cytopathology, were responsible for the developmental abnormalities in the
CNS observed in infected mice (29). Although studies of other viral infections have
documented the contribution of inflammatory responses to tissue pathology, our
findings were novel in that virus-induced inflammation was associated with focal,
nonfatal viral encephalitis that resulted in global and symmetric abnormalities in CNS
development without significant destruction of brain parenchyma. Together, our find-
ings argue that a balance between control of viral replication and the development of
immunopathology must be achieved to limit disease in the developing brain (28, 29).
In the current study, we attempted to further define specific inflammatory mediators
that contributed to the altered CNS development induced by the virus. Our studies
demonstrated that treatment with TNF-NAbs efficiently decreased CNS inflammation
and limited deficits in cerebellar development in MCMV-infected neonatal mice, clearly
implicating this proinflammatory molecule in the pathogenesis of the infection. Al-
though TNF- has pleiotropic effects in vivo, our findings argued that treatment with
TNF-NAb decreased CNS inflammation by decreasing the frequency of activated CD45
Ly6Chi CD11b CCR2 iMo in the brain. Furthermore, our data also suggested that
TNF-NAb decreased infiltration of blood iMo into the brains of infected mice by
reducing their numbers in peripheral blood and not by directly decreasing the activa-
tion state of iMo in the brains of infected animals. Findings from previous studies in
WNV encephalitis models have also argued that infiltration of iMo into the brains of
WNV-infected mice was dependent on CCR2/CCL2 monocytosis in peripheral blood and
not secondary to CCR2/CCL2-driven recruitment of iMo to the infected brain (73, 86). It
is also of interest that MCMV infection of adult mice results in Myd88-dependent
mobilization and activation of monocytes in the bone marrow and that, in contrast to
type I IFNs, IL-6, or IL-1, TNF- appeared to potentially have a direct role in mobilization
and activation of monocytes from the bone marrow (87). Although our results are
consistent with TNF-NAb inhibition of mobilization and activation of monocytes from
the bone marrow and decreased blood and brain iMo, it is important to note that these
observations were made in adult mice, in which the bone marrow is a major source of
myeloid mononuclear cells.
TNF- has been shown to function in the recruitment of peripheral monocytes to
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sites of injury in experimental models of inflammatory disease in different organ
systems, including the CNS. Studies in a murine model of Listeria monocytogenes have
demonstrated that peripheral infection and innate responses, including IFN- and
TNF- production, were associated with an upregulation of proinflammatory genes and
the induction of adhesion molecules and chemokines in the CNS (88, 89). In addition,
in some models of virus infection of the brain by a systemic route, monocytes
expressing Ly6C infiltrated the brain prior to CNS infection, suggesting that peripheral
responses to infection contributed to recruitment of proinflammatory monocytes into
the brain (88). Recruitment of proinflammatory monocytes to the CNS and other tissues
following infection has been argued to be dependent on MCP-1 and MCP-3 (90, 91). As
MCP-1 is a high-affinity ligand of CCR2, our findings were consistent with these earlier
studies that had described MCP-1-mediated recruitment of activated CCR2 peripheral
blood MNCs into the CNS. However, it should be noted that in more recent studies, the
recruitment of inflammatory monocytes from the blood to tissue has been shown to be
independent of CCR2 expression by iMo and that MCP-1 appears to function primarily
by increasing mobilization of monocytes from the bone marrow (89). Thus, in our study,
the depletion of blood iMo by TNF-NAb treatment appears to be the most likely
mechanism for the decrease of iMo in the brains of MCMV-infected mice, but we cannot
exclude the possibility that some of the decrease was secondary to the decrease in the
frequency of proinflammatory resident cells of the brain, including microglia. Finally, it
is important to note that although treatment with TNF-NAb dramatically reduced the
frequency of activated microglia in the brains of infected animals to levels measured in
mock-infected animals, iMo that infiltrated the brains of TNF-NAb-treated animals
continued to express activation markers, providing evidence that resident cells of the
infected brain are not the sole determinants of inflammation in the brain in infected
animals.
Studies in other small-animal models of virus-induced CNS disease associated with
inflammation have described the importance of infiltrating monocytes in the induction
of disease (38, 74, 92). Furthermore, limiting the infiltration of peripheral blood mono-
cytes, including the Ly6Chi CCR2 subset, into the CNS resulted in improved disease
outcomes in murine models of amyotrophic lateral sclerosis (ALS), demyelinating
diseases associated with virus infection, experimental autoimmune encephalitis (EAE),
and CNS ischemia (67, 69, 93, 94). Early studies described a proinflammatory phenotype
of CNS-infiltrating monocytes (CD45hi), often together with the expression of MHC-II
and/or other activation markers (95). More recently, proinflammatory monocytes infil-
trating the CNS have been defined by the expression of CCR2 and Ly6C, and in some
cases together with activation markers (67, 96). These markers define M1 monocytes,
thought to have a major role in the early response to tissue injury/infection and
associated with immunopathology (96).
The role of iMo in resistance to viral infection of the brain has been most extensively
studied in recent years in the mouse of model of WNV encephalitis (97). iMo are
thought to play a critical role in resistance to lethal encephalitis in this model, as
depletion of iMo through the use of transgenic mice, chemical treatments, or biologics,
such as anti-TNF monoclonal antibodies (MAbs), has resulted in increased levels of virus
replication in the brain and decreased survival of WNV-infected mice. In contrast to
these findings, other authors have argued that a reduction in the infiltration of Ly6Chi
mononuclear cell infiltration into the CNS of WNV-infected mice prolonged survival of
the infection, an effect that at least one study suggested was independent of the level
of virus replication (98). Validation of these initial findings was reported in a study from
the same group of investigators, who demonstrated that depletion of inflammatory
monocytes (CD45 CD11b Ly6Chi) with microparticles improved the survival and
outcome of WNV-infected mice, an outcome that was associated with a decrease in the
brain infiltration of iMo (99). Similar to our findings, the impact of the microparticle
treatment leading to decreased CNS infiltration of iMo appeared to be secondary to
depletion of these cells in the peripheral blood and not loss of iMo that had entered the
brain (99). Our findings in this model of CMV infection of the developing brain are
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consistent with results from this study of WNV infection of the CNS and argued that
decreased infiltration of iMo into the brain limited the neurodevelopmental abnormal-
ities in MCMV-infected mice. Although clearance of virus from the brain by virus-
specific CD8 T lymphocytes is critical to both model systems, several features of our
system utilizing MCMV are notably different than WNV models of CNS infection and
could account for some of the discordance between findings in WNV encephalitis in
adult mice and MCMV focal CNS infection in newborn mice (28, 100, 101). These
differences include (i) the nature of the encephalitis induced by the two viruses; (ii) the
developmental status of the infected animal; and importantly, (ii) the limited neurot-
ropism of MCMV compared to WNV. In contrast to direct virus-induced neurological
damage postulated in WNV encephalitis, our findings in this murine model of CMV
brain infection demonstrated that the interface between early effector functions in
virus-induced inflammation and the developing brain likely contributed to the neuro-
logical damage that resulted from the infection.
In this model of CMV infection of the developing brain, robust activation of
microglia and infiltration of Ly6Cint CD11blow/ cells into the CNS was observed in
MCMV-infected mice (Fig. 6E and 9). The Ly6Cint CD11blow/ population was comprised
of about 50% NK cells, a finding that was consistent with their production of high levels
of IFN- (Fig. 10A). Thus, in light of recent studies suggesting a role for NK cells in
murine models of demyelinating diseases, such as EAE, and virus-induced demyelina-
tion, we cannot exclude the potential contribution of infiltrating NK cells to the
inflammation in the brains of MCMV-infected mice (102, 103). Similarly, NK cells have
been proposed to provide protective antiviral activities in models of viral encephalitis,
including coronavirus encephalitis, although the precise role of NK cells in WNV
encephalitis remains less well understood (104, 105). However, it is important to note
that NK cell function in neonatal mice is developmentally immature and cannot be
compared to results from studies in adult mice (106). In contrast, activated microglia
have been suggested to contribute immunopathological responses to chronic viral
infections of the CNS, such as HIV, as well as to provide early antiviral responses during
acute viral encephalitis associated with both flaviviruses and herpes simplex virus
(107–109). However, similar to limitations in our study, the previous studies were
often carried out in the presence of peripheral inflammatory responses, and thus,
the precise role of microglia in the mechanisms of CNS disease cannot be rigorously
assigned. Regardless of the role of microglia or NK cells, neutralization of TNF-
resulted in the decreased transcription of IL-1, IFN-, and IFN- (in addition to
TNF-) in the cerebellum, as well as decreased expression of proinflammatory
chemokines. Collectively, our findings demonstrated that TNF-NAb treatment de-
creased the frequency of activated microglia and infiltration of both iMo and NK
cells into the brains of MCMV-infected mice and thus argued that TNF- was a key
initiator of inflammation in the brains of MCMV-infected mice.
In summary, our findings demonstrated that treatment of MCMV-infected neonatal
mice with TNF-NAbs dramatically decreased CNS inflammation and resulted in normal-
ization of neurodevelopmental markers. TNF-NAb treatment did not significantly alter
the levels of virus replication in the CNS, providing further evidence that virus-induced
inflammation, and not the direct effects of virus infection, was responsible for the
developmental abnormalities in the brains of MCMV-infected mice. Specific mecha-
nisms of action of TNF--induced inflammation in the CNS remain incompletely de-
fined, but a major effect of TNF-NAb treatment was the decreased infiltration of
activated Ly6Chi CCR2 iMo into the brains of infected mice secondary to the loss of
iMo from the peripheral blood. Thus, if a similar TNF--regulated pathway represents a
mechanism of damage and neurodevelopmental deficits found in infants following
intrauterine infection with HCMV, then interventions modulating the trafficking of iMo
from the peripheral blood into the CNS could offer a therapeutic approach for preven-
tion of neurologic sequelae characteristic of this intrauterine infection.
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Ethics statement. The University of Alabama—Birmingham (UAB) Institutional Animal Care and Use
Committee (IACUC) guidelines were followed for all animal experiments and breeding. These guidelines
are in strict compliance with the NIH (Office of Laboratory Animal Welfare [OLAW] assurance number
A32555-01) guidelines. Animals were euthanized with carbon dioxide under regulated flow. Following
carbon dioxide administration, cervical dislocation was implemented to ensure the animals were
completely euthanized prior to carrying out experimental protocols, according to the UAB Animal
Resource Program (ARP) guidelines. An approved protocol was obtained from the IACUC for all
experiments. All the experiments done at the University of Rijeka were in accordance with the University
of Rijeka, Croatia, animal use and care policies and the guidelines of the animal experimentation law (SR
455.163; Töten von Versuchstieren [TVV]) of the Swiss Federal Government.
MCMV infection and TNF-NAb treatment. BALB/cJ mice were purchased from the Jackson Labo-
ratory (Bar Harbor, ME). Mouse pups were infected with 500 PFU of MCMV Smith (ATCC VR-1399) in 50
l of sterile 1 phosphate-buffered saline (PBS). Virus was delivered by intraperitoneal (i.p.) injection of
newborn BALB/c mice no more than 12 h following birth, as previously described (26, 29). On PND 4 to
7, pups were treated by i.p. injection with neutralizing rat monoclonal antibodies to TNF- (kindly
provided by David Shealy, Janssen Pharmaceuticals, Titusville, NJ) at 500 g/mouse/day. TNF-NAbs were
diluted in 1 PBS. As a control, uninfected and MCMV-infected animals were given i.p. injections with 500
g/mouse/day of rat IgG2a (isotype control) antibodies, also diluted in 1 PBS. Control and MCMV-infected
mice that were not treated with either TNF-NAbs or isotype antibodies received a vehicle injection of sterile
1 PBS alone. For all treatments, a volume of 50 l was administered. On PND 8, between 16 and 18 h
post-final treatment, the mice were sacrificed and perfused with ice-cold PBS, and organs were harvested.
Once isolated, the organs were prepared for the appropriate assay. Infection of newborn mouse pups was
confirmed by quantitative real-time PCR measurement of MCMV genome equivalents, as previously de-
scribed, using the StepOne Plus system from Applied Biosystems (Carlsbad, CA) (29).
Cytokine measurements. For analysis of cytokine/chemokine levels in the cerebellum, 3 cerebella
were pooled, weighed, and homogenized, utilizing a Dounce homogenizer, on ice in 600 l of 1 PBS,
0.1% Triton X-100 plus a protease/phosphatase inhibitor cocktail with EDTA (Thermo Scientific, Waltham,
MA). The homogenates were then sonicated 3 times for 10 s each time with a 10-s incubation on ice
between sonications. Samples were then centrifuged at 14,000 rpm for 30 min at 4°C. Following
centrifugation, the samples were aliquoted and stored at 80°C until use. Cerebellar cytokine/
chemokine levels were determined by Milliplex map multiplex assay (Millipore, Billerica, MA)
according to the manufacturer’s instructions. Cytokine levels in the sera of control and MCMV-infected
mice were determined by Bioplex cytokine assay (Bio-Rad, Hercules, CA) using the protocol provided by
the manufacturer.
Immunofluorescence, immunohistochemistry, and cerebellar morphometry. Immunofluores-
cent staining of BrdU and Ki67 was performed by previously published methods (29). Briefly, mice were
injected on PND 8 with 50 g/g of body weight of BrdU (Sigma-Aldrich) 6 h prior to sacrifice. The mice
were perfused with PBS, and their brains were fixed in 4% paraformaldehyde (PFA) overnight, cryopro-
tected in 30% sucrose-PBS, and embedded in Tissue Tek OCT compound (Andwin Scientific); 8-m
sagittal sections were cut using a Leica cryostat and then dried for 4 h at room temperature (RT),
rehydrated in 1 PBS, and used for immunofluorescence assays. The sections were blocked for 1 h at RT,
followed by a 2 N HCl acid wash. The sections were then buffered in 0.1 M borate buffer, washed, and
incubated in primary antibody overnight at RT. The following day, the sections were washed and incubated
in secondary antibody for 2 h at RT in the dark. The sections were again washed and incubated with Hoescht
stain (in 1 PBS) for 15 min at RT in the dark and then mounted using Vectashield fluorescent mounting
medium (Vector Laboratories).
Staining for Iba-1 and CD169 was as follows. Sections were blocked in 1 PBS, 0.05% Triton X-100,
20% normal goat serum, 5% bovine serum albumin (BSA) for 2 h at RT. The sections were then washed
in 1 PBS, 0.01% Triton X-100 and stained with primary antibodies (in blocking buffer) at RT for 2 h.
Subsequently, the sections were washed 3 times for 5 min/wash with 1 PBS, 0.01% Triton X-100 and
then incubated for 2 h at RT in the dark with secondary antibodies (in blocking buffer). After incubation
with secondary antibodies, the sections were washed 5 times for 5 min/wash with 1 PBS, 0.01% Triton
X-100 and incubated with Hoescht stain (in 1 PBS) for 15 min at RT. Following nuclear staining with
Hoescht stain, the sections were washed 3 times for 5 min/wash with 1 PBS and then postfixed with
4% PFA for 15 min at RT. The sections were washed 5 times for 2 min/wash following postfixing and then
mounted with Vectashield.
The primary antibodies used were as follows: rat anti-BrdU (1:50; ab6326; Abcam), rabbit anti-Ki67
(1:200; ab66155; Abcam), rabbit anti-Iba-1 (1:200; Wako, Japan), and rat anti-CD169 (1:100; BioLegend).
The secondary antibodies used were goat anti-rabbit tetramethyl rhodamine isocyanate (TRITC)/ fluo-
rescein isothiocyanate (FITC) and goat anti-rat TRITC/FITC (1:150; Southern Biotech, Birmingham, AL).
Hoescht stain (1:1,000; Thermo Scientific) was used as a nuclear marker. Images of stained sections were
collected with an Olympus (Center Valley, PA) FluoView FV1000 confocal microscope at either 40
magnification or60 magnification, as indicated. For all images, the imaging medium used was Olympus
oil, and all images were captured using FluoView software. All morphometric measurements and cell
counts were done as previously described and analyzed using Image J software according to our
previous protocol (29, 110).
Quantitative real-time reverse transcription-PCR. TRIzol reagent (Roche Applied Science, Indi-
anapolis, IN) was used to isolate total RNA from the cerebellum, as described previously (29). The
Invitrogen Superscript III First Strand synthesis kit was used to synthesize cDNA, and real-time
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reverse transcription-PCR was performed according to our previous protocol. TaqMan assay mixtures
from Applied Biosystems (Life Technologies, Carlsbad, CA) were used for TNF- (Mm99999068),
MCP-1 (Mm00656886), IFN- (Mm00439552), STAT1 (Mm00439518), IFN- (Mm99999071), IFIT1
(Mm00515153), IL-1 (Mm00434228), IRF7 (Mm00516793), gli1 (Mm00494645), N-myc (Mm00476449), Tiam1
(Mm01170430), CDK5 (Mm00432437), and GABRA6 (Mm01227754). The Applied Biosystems StepOne Plus
real-time PCR machine was used to analyze gene transcription. Fold changes for all experimental groups
were normalized to control values (termed the relative fold change).
Virus genome copy quantitation. The liver was collected from each animal, as well as a small piece
of spleen, brain, and cerebellum (50 mg) randomly collected for the analysis of viral genome copies by
quantitative PCR (qPCR), as we have described in previous publications (26, 29). The results were
expressed as log genome copies per milligram of tissue.
Flow cytometry, acquisition, and sorting. For all flow cytometry experiments, tissue or blood was
pooled from 3 or 4 animals, and each experiment was repeated a minimum of 3 times. Following CO2
euthanasia, about 150 to 200 l of whole blood was obtained from the axillary arteries and by cardiac
puncture. Then, the brain was dissected from ice-cold-PBS-perfused mice. Following dissection, the
organs were dissociated in a Gentle-Macs (Milteny, Auburn, CA) apparatus, and the cell suspensions were
cleared through 40-m (blood) or 70-m (brain) strainers before being subjected to centrifugation at
600  g for 30 min over a 30%-70% discontinuous Percoll gradient for blood or 690  g for 20 min over
a 37.5% continuous Percoll gradient for brain. The mononuclear cell pellet (brain) or the band formed at
the 30%-70% interphase (blood) were collected, washed once in RPMI medium and in FACS buffer before
incubation for 30 min on ice with Fc-block (1:100; CD16/CD32; BioLegend, San Diego, CA). Subsequently,
the cell suspensions were pelleted, resuspended in the appropriate staining cocktail, and incubated for
30 min at 4°C. Following two washes in Dulbecco’s phosphate-buffered saline (DPBS), the cells were
incubated for another 20 min at 4°C, with the fixable viability dye eFluor 450 (eBiosiences, San Jose, CA)
to allow LIVE/DEAD cell discrimination. The cells were subsequently washed twice in DPBS before being
fixed in 2% PFA for 15 min at 4°C. Following 2 washes in PBS, the cells were resuspended in FACS buffer,
and flow cytometry acquisition was conducted on a FACSVerse (BD Biosciences, San Jose, CA.) analyzer.
The data were analyzed using FlowJo V10.0.8r1. For cell sorting, we followed the same procedure, except
that the cells were not fixed in PFA before being subjected to 4-way cell sorting in a BD FACSAria
instrument (BD Biosciences, San Jose, CA) at the UAB Comprehensive Flow Cytometry Core (NIH P30
AR048311, Rheumatic Disease Core Center [RDCC], NIH P30 AI27667, Center for AIDS Research [CFAR]).
The sorted cells were collected in RPMI (10% fetal bovine serum [FBS]) before being lysed in GTC RNA
lysis buffer (Omega Bio-tek, Norcross, GA). The different antibodies, isotype controls, and corresponding
fluorochromes used in this work were as follows: FITC-anti-CD80 (clone 16-10A1; eBiosciences), FITC-
anti-CD45 (clone 30-F11; eBiosciences), phycoerythrin (PE)-conjugated anti-CCR2 (475301; RD Systems),
PE-conjugated anti-CD3e chain (clone 145-2c11; BD Pharmingen), peridinin chlorophyll protein (PerCP)-
Cy5.5-conjugated anti-Ly6C (clone HK1.4; eBiosciences), PE-Cy7-conjugated IA/IE (i.e., MHC-II subclasses
H2A and H2E) (clone M5/114.15.2; BioLegend), allophycocyanin (APC)-CD11b (clone M1/70; eBiosci-
ences), AF660-conjugated anti-NKp46 (clone 29A1.4; eBiosciences), APC-Cy7 anti-CD11b (M1/70; BD
Biosciences), BV510-conjugated anti-CD45 (clone 30-F11; BD Biosciences), TruStainfc anti-CD16/CD32
(clone 93; BioLegend), and the fixable viability dye eFluor V450 (eBiosciences).
Statistics. For all comparisons between mean values from control and infected animals, a two-tailed
t test was used to determine statistical significance. Two-way analysis of variance (ANOVA), followed by
Bonferronni’s posttest, was used to determine significance across treatment groups. Median viral
genome copy numbers were analyzed using a Kruskal-Wallis test of medians with Dunn posttest
correction. All statistical analysis was carried out using Prism 5 software (GraphPad, San Diego, CA).
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